TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering
December 22, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
December 10, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment
November 23, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines
November 16, 2020 09:45 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:03 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
November 03, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma
October 26, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer
September 21, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
September 03, 2020 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...